Pomerantz Law Firm Launches Investigation into argenx SE for Possible Securities Fraud Amid FDA Alerts
On July 31, 2025, the Pomerantz Law Firm announced its investigation into potential claims on behalf of investors of argenx SE, a biotech company listed on NASDAQ under the symbol ARGX. This investigation has arisen due to serious allegations regarding possible securities fraud or other unlawful practices allegedly perpetrated by argenx and some of its officers and directors. Investors concerned about their investment in argenx have been encouraged to reach out to Danielle Peyton of Pomerantz for further guidance.
The backdrop for this investigation involves a recent alert from the U.S. Food and Drug Administration (FDA) dated June 30, 2025. This alert highlighted serious risks associated with argenx's product, Vyvgart Hytrulo. The FDA noted that reports to their Adverse Event Reporting System indicated a potential risk of severe deterioration in patients suffering from chronic inflammatory demyelinating polyradiculoneuropathy. The implication of this risk compelled the FDA to evaluate the need for regulatory action regarding the product's safety profile.
This alarming news prompted a notable reaction from the stock market; on the same day, argenx's American Depositary Share (ADS) saw a decline, falling $8.92 or 1.59%, closing at $551.22. This sharp decline indicates the concern and potential panic among investors following the FDA’s announcement and raises questions about the internal oversight and accountability mechanisms at argenx.
Pomerantz LLP is a well-respected law firm that has carved out a niche in corporate, securities, and antitrust litigation, with a longstanding reputation in the field of securities class actions. Founded over 85 years ago, the firm was established by Abraham L. Pomerantz, a significant figure known as the 'dean' of securities litigation. Pomerantz has continued this legacy, fighting on behalf of investors who feel wronged due to fraudulent practices, breaches of fiduciary duty, or other forms of corporate misconduct.
The firm claims to have successfully obtained numerous multimillion-dollar awards for those impacted by such illicit activities in the past. As part of their ongoing investigation concerning argenx, they are exploring the ramifications of the recent FDA alerts and how these may connect to the company's alleged misrepresentations or negligence.
Those who believe they may have suffered losses due to their investment in argenx are urged to get in touch with Pomerantz LLP for further assistance. The firm is dedicated to ensuring that investors have the opportunity to seek compensation for potential damages incurred due to wrongdoing on the part of public companies. They can be contacted by email or phone through the details provided in their press release.
In the volatile world of biotech stocks, where regulatory approvals can dramatically impact company fortunes, the obligations to provide accurate and timely information to investors are paramount. This ongoing investigation will be scrutinized closely, particularly by those who have invested in argenx, as the outcome could affect not just their financial health, but also the integrity of the market as it pertains to corporate disclosures and accountability. As the situation evolves, investors are urged to stay informed and take appropriate action if necessary.
The backdrop for this investigation involves a recent alert from the U.S. Food and Drug Administration (FDA) dated June 30, 2025. This alert highlighted serious risks associated with argenx's product, Vyvgart Hytrulo. The FDA noted that reports to their Adverse Event Reporting System indicated a potential risk of severe deterioration in patients suffering from chronic inflammatory demyelinating polyradiculoneuropathy. The implication of this risk compelled the FDA to evaluate the need for regulatory action regarding the product's safety profile.
This alarming news prompted a notable reaction from the stock market; on the same day, argenx's American Depositary Share (ADS) saw a decline, falling $8.92 or 1.59%, closing at $551.22. This sharp decline indicates the concern and potential panic among investors following the FDA’s announcement and raises questions about the internal oversight and accountability mechanisms at argenx.
Pomerantz LLP is a well-respected law firm that has carved out a niche in corporate, securities, and antitrust litigation, with a longstanding reputation in the field of securities class actions. Founded over 85 years ago, the firm was established by Abraham L. Pomerantz, a significant figure known as the 'dean' of securities litigation. Pomerantz has continued this legacy, fighting on behalf of investors who feel wronged due to fraudulent practices, breaches of fiduciary duty, or other forms of corporate misconduct.
The firm claims to have successfully obtained numerous multimillion-dollar awards for those impacted by such illicit activities in the past. As part of their ongoing investigation concerning argenx, they are exploring the ramifications of the recent FDA alerts and how these may connect to the company's alleged misrepresentations or negligence.
Those who believe they may have suffered losses due to their investment in argenx are urged to get in touch with Pomerantz LLP for further assistance. The firm is dedicated to ensuring that investors have the opportunity to seek compensation for potential damages incurred due to wrongdoing on the part of public companies. They can be contacted by email or phone through the details provided in their press release.
In the volatile world of biotech stocks, where regulatory approvals can dramatically impact company fortunes, the obligations to provide accurate and timely information to investors are paramount. This ongoing investigation will be scrutinized closely, particularly by those who have invested in argenx, as the outcome could affect not just their financial health, but also the integrity of the market as it pertains to corporate disclosures and accountability. As the situation evolves, investors are urged to stay informed and take appropriate action if necessary.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.